Peter Lynch · Growth at a reasonable price (GARP)
Is Xeris Biopharma Holdings, Inc. (XERS) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
84/100
Mixed
3/6 criteria passed
Peter Lynch's Criteria, Applied to XERS
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
55.8%
Net margin > 0
3.8%
How XERS Scores on Other Strategies
Live Financial Snapshot
Market cap
$1.95B
P/E (TTM)
-
ROIC (TTM)
8.83%
Gross margin
85.41%
Other Peter Lynch fit reports
Frequently Asked Questions
What is XERS's Peter Lynch fit score?
XERS scores 84/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own XERS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends XERS.
How often is this score updated?
XERS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends XERS.
